Anti-Müllerian hormone levels and antral follicle count in women enrolled in in vitro fertilization cycles: Relationship to lifestyle factors, chronological age and reproductive history

References

• van Rooij I A, Broekmans F J, te Velde E R, Fauser B C, Bancsi L F, de Jong F H, Themmen A P. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002; 17: 3065–3071
   PubMed Web of Science ®Google Scholar
• Tremellen K P, Kolo M, Gilmore A, Lekamge D N. Anti-müllerian hormone as a marker of ovarian reserve. Aust N Z J Obstet Gynecol 2005; 45: 20–24
   PubMed Web of Science ®Google Scholar
• de Vet A, Laven J S, de Jong F H, Themmen A P, Fauser B C. Anti-müllerian hormone a putative marker for ovarian aging. Fertil Steril 2002; 77: 357–362
   PubMed Web of Science ®Google Scholar
• Fanchin R, Schonäuer L M, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum anti-Müllerian hormone is more strongly related to ovaran follicular status than inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 2003; 18: 323–327
   PubMed Web of Science ®Google Scholar
• Muttukrishna S, Suharjono H, McGarrigle H, Sathanandan M. Inhibin B and anti-Müllerian hormone: markers of ovarian response in IVF/ICSI patients?. Br J Obstet Gynaecol 2004; 111: 1248–1253
   Google Scholar
• Fanchin R, Taieb J, Lozano D H, Ducot B, Frydman R, Bouyer J. High reproducibility of serum anti-müllerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod 2005; 20: 923–927
   PubMed Web of Science ®Google Scholar
• Visser J A, Themmen A P. Anti-müllerian hormone and folliculogenesis. Mol Cell Endocrinol 2004; 234: 81–86
   Google Scholar
• Josso N, di Clemente N. TGF-β family members and gonadal development. Trends Endocrinol Metab 1999; 10: 216–222
   Google Scholar
• Lee M M, Donahoe P K. Mullerian inhibiting substance: a gonadal hormone with multiple functions. Endocr Rev 1993; 14: 152–164
   PubMed Web of Science ®Google Scholar
• Rajpert-De Meyts E, Jorgensen N, Graem N, Muller J, Cate R L, Skakkebaek N E. Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J Clin Endocrinol Metab 1999; 84: 3836–3844
   PubMed Web of Science ®Google Scholar
• Lee M M, Donahoe P K, Hasegawa T, Silverman B, Crist G B, Best S, Hasegawa Y, Noto R A, Schoenfeld D, MacLaughlin D T. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 1996; 81: 571–576
   PubMed Web of Science ®Google Scholar
• Durlinger A L, Visser J A, Themmen A P. Regulation of ovarian function: the role of anti-müllerian hormone. Reproduction 2002; 124: 601–609
   PubMed Web of Science ®Google Scholar
• Baarends W M, Uilenbroek J T, Kramer P, Hoogerbrugge J W, van Leeuwen E C, Themmen A P, Grootegoed J A. Anti-Müllerian hormone and anti-Müllerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotrophin-induced follicle growth. Endocrinology 1995; 136: 4951–4962
   PubMed Web of Science ®Google Scholar
• Vigier B, Picard J Y, Tran D, Legeai L, Josso N. Production of anti-Müllerian hormone: another homology between Sertoli and granulosa cells. Endocrinology 1984; 114: 1315–1320
   PubMed Web of Science ®Google Scholar
• Cook C L, Siow Y, Taylor S, Fallat M E. Serum müllerian-inhibiting substance levels during normal menstrual cycles. Fertil Steril 2000; 73: 859–861
   PubMed Web of Science ®Google Scholar
• Weenen C, Laven J S, von Bergh A R, Cranfield M, Groome N P, Visser J A, Kramer P, Fauser B C, Themmen A P. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004; 10: 77–83
   PubMed Web of Science ®Google Scholar
• Fauser B C, van Heusden A M. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev 1997; 18: 71–106
   PubMed Web of Science ®Google Scholar
• Ueno S, Takahashi M, Manganaro T F, Ragin R C, Donahoe P K. Cellular localization of müllerian inhibiting substance in the developing rat ovary. Endocrinology 1989; 124: 1000–1006
   PubMed Web of Science ®Google Scholar
• Durlinger A L, Kramer P, Karels B, de Jong F H, Uilenbroek J T, Grootegoed J A, Themmen A P. Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology 1999; 140: 5789–5796
   PubMed Web of Science ®Google Scholar
• Durlinger A L, Gruijters M J, Kramer P, Karels B, Kumar T R, Matzuk M M, Rose U M, de Jong F H, Uilenbroek J T, Grootegoed J A, et al. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 2001; 142: 4891–4899
   PubMed Web of Science ®Google Scholar
• Durlinger A L, Gruijters M J, Kramer P, Karels B, Ingraham H A, Nachtigal M W, Uilenbroek J T, Grootegoed J A, Themmen A P. Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology 2002; 143: 1076–1084
   PubMed Web of Science ®Google Scholar
• Scheffer G J, Broekmans F J, Dorland M, Habbema J D, Looman C W, te Velde E R. Antral follicle counts by transvaginal ultrasonography are related to age in women with proven natural fertility. Fertil Steril 1999; 72: 845–851
   PubMed Web of Science ®Google Scholar
• Scheffer G J, Broekmans F J, Looman C W, Blankenstein M, Fauser B C, te Jong F H, te Velde E R. The number of antral follicles in normal women with proven fertility is the best reflection of reproductive age. Hum Reprod 2003; 18: 700–706
   PubMed Web of Science ®Google Scholar
• Seifer D B, MacLaughlin D T, Christian B P, Bo Feng B A, Shelden R M. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002; 77: 468–471
   PubMed Web of Science ®Google Scholar
• Hazout A, Bouchard P, Seifer D B, Aussage P, Junca A M, Cohen-Bacrie P. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril 2004; 82: 1323–1329
   PubMed Web of Science ®Google Scholar
• Muttukrishna S, McGarrigle H, Wakim R, Khadum I, Ranieri D M, Serhal P. Antral follicle count, anti-müllerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology?. Br J Obstet Gynaecol 2005; 112: 1384–1390
   Google Scholar
• Visser J A, de Jong F H, Laven J S, Themmen A P. Anti-müllerian hormone: a new marker for ovarian function. Reproduction 2006; 131: 1–9
   PubMed Web of Science ®Google Scholar
• Long W Q, Ranchin V, Pautier P, Belville C, Denizot P, Cailla H, Lhommé C, Picard J Y, Bidart J M, Rey R. Detection of minimal levels of serum anti-Mullerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 2000; 85: 540–544
   PubMed Web of Science ®Google Scholar
• te Velde E R. Disappearing ovarian follicles and reproductive ageing. Lancet 1993; 341: 1125–1126
   Google Scholar
• Scott R T, Jr, Hofmann G E. Prognostic assessment of ovarian reserve. Fertil Steril 1995; 63: 1–11
   PubMed Web of Science ®Google Scholar
• Toner J P, Philput C, Jones G S, Muasher S J. Basal follicle-stimulating hormone level is a better predictor of in vitro fertilization performance than age. Fertil Steril 1991; 55: 784–791
   PubMed Web of Science ®Google Scholar
• Bancsi L F, Broekmans F J, Eijkemans M J, de Jong F H, Habbema J D, te Velde E R. Predictors of poor ovarian response in in-vitro fertilization: a prospective study comparing basal markers of ovarian reserve. Fertil Steril 2002; 77: 328–336
   PubMed Web of Science ®Google Scholar
• Fleming R, Deshpande N, Traynor I, Yates R WS. Dynamics of FSH-induced follicular growth in subfertile women: relationship with age, insulin resistance, oocyte yield and anti-Mullerian hormone. Hum Reprod 2006; 21: 1436–1441
   PubMed Web of Science ®Google Scholar
• Hassan M A, Killick S R. Negative lifestyle is associated with a significant reduction in fecundity. Fertil Steril 2004; 81: 384–392
   PubMed Web of Science ®Google Scholar
• Palmer J R, Rosenberg L, Wise L A, Horton N J, Adams-Campbell L L. Onset of natural menopause in African American women. Am J Public Health 2003; 93: 299–306
   PubMed Web of Science ®Google Scholar
• Laven J S, Mulders A G, Visser J A, Themmen A P, de Jong F H, Fauser B C. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004; 89: 318–323
   PubMed Web of Science ®Google Scholar
• Ortiz A P, Harlow S D, Sowers M, Nan B, Romaguera J. Age at natural menopause and factors associated with menopause state among Puerto Rican women aged 40–59 years, living in Puerto Rico. Menopause 2006; 13: 116–124
   PubMed Web of Science ®Google Scholar
• Gold E B, Bromberger J, Crawford S, Samuels S, Greendale G A, Harlow S D, Skurnick J. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol 2001; 153: 865–874
   PubMed Web of Science ®Google Scholar
• Neal M S, Hughes E G, Holloway A C, Foster W G. Sidestream smoking is equally as damaging as mainstream smoking on IVF outcomes. Hum Reprod 2005; 20: 2531–2535
   PubMed Web of Science ®Google Scholar
• Bellver J, Melo M, Bosch E, Islas J, Serra V, Remohí J, Pellicer A. Obesity and poor reproductive outcome: the subtle role of endometrium. Hum Reprod 2006; 21(Suppl. 1)i119
   Google Scholar
• Fedorcsák P, Dale P O, Storeng R, Ertzeid G, Bjercke S, Oldereid N, Omland A K, Abyholm T, Tanbo T. Impact of overweight and underweight on assisted reproduction treatment. Hum Reprod 2004; 19: 2523–2528
   PubMed Web of Science ®Google Scholar
• Balen A H, Platteau P, Andersen A N, Devroey P, Sørensen P, Helmgaard L, Arce J C. The influence of body weight on response to ovulation induction with gonadotrophins in 335 women with World Health Organization group II anovulatory infertility. Br J Obstet Gynaecol 2006; 113: 1195–1202
   Google Scholar